171 related articles for article (PubMed ID: 36289399)
21. Bamlanivimab therapy for acute COVID-19 does not blunt SARS-CoV-2-specific memory T cell responses.
Ramirez SI; Grifoni A; Weiskopf D; Parikh UM; Heaps A; Faraji F; Sieg SF; Ritz J; Moser C; Eron JJ; Currier JS; Klekotka P; Sette A; Wohl DA; Daar ES; Hughes MD; Chew KW; Smith DM; Crotty S;
JCI Insight; 2022 Dec; 7(24):. PubMed ID: 36378539
[TBL] [Abstract][Full Text] [Related]
22. Modeling the emergence of viral resistance for SARS-CoV-2 during treatment with an anti-spike monoclonal antibody.
Phan T; Zitzmann C; Chew KW; Smith DM; Daar ES; Wohl DA; Eron JJ; Currier JS; Hughes MD; Choudhary MC; Deo R; Li JZ; Ribeiro RM; Ke R; Perelson AS;
bioRxiv; 2023 Sep; ():. PubMed ID: 37745410
[TBL] [Abstract][Full Text] [Related]
23. Emergence of Q493R mutation in SARS-CoV-2 spike protein during bamlanivimab/etesevimab treatment and resistance to viral clearance.
Guigon A; Faure E; Lemaire C; Chopin MC; Tinez C; Assaf A; Lazrek M; Hober D; Bocket L; Engelmann I; Alidjinou EK
J Infect; 2022 Feb; 84(2):248-288. PubMed ID: 34437928
[No Abstract] [Full Text] [Related]
24. Monoclonal antibody treatment drives rapid culture conversion in SARS-CoV-2 infection.
Boucau J; Chew KW; Choudhary M; Deo R; Regan J; Flynn JP; Crain CR; Hughes MD; Ritz J; Moser C; Dragavon JA; Javan AC; Nirula A; Klekotka P; Greninger AL; Coombs RW; Fischer WA; Daar ES; Wohl DA; Eron JJ; Currier JS; Smith DM; Li JZ; Barczak AK;
medRxiv; 2021 Dec; ():. PubMed ID: 35018382
[TBL] [Abstract][Full Text] [Related]
25. Susceptibility of SARS-CoV-2 Omicron Variants to Therapeutic Monoclonal Antibodies: Systematic Review and Meta-analysis.
Tao K; Tzou PL; Kosakovsky Pond SL; Ioannidis JPA; Shafer RW
Microbiol Spectr; 2022 Aug; 10(4):e0092622. PubMed ID: 35700134
[TBL] [Abstract][Full Text] [Related]
26. Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial.
Brown LK; Freemantle N; Breuer J; Dehbi HM; Chowdhury K; Jones G; Ikeji F; Ndoutoumou A; Santhirakumar K; Longley N; Checkley AM; Standing JF; Lowe DM
Trials; 2021 Mar; 22(1):193. PubMed ID: 33685502
[TBL] [Abstract][Full Text] [Related]
27. Neutralizing Antibody Therapeutics for COVID-19.
Hurt AC; Wheatley AK
Viruses; 2021 Apr; 13(4):. PubMed ID: 33916927
[TBL] [Abstract][Full Text] [Related]
28. Emergence and onward transmission of a SARS-CoV-2 E484K variant among household contacts of a bamlanivimab-treated patient.
Sabin AP; Richmond CS; Kenny PA
Diagn Microbiol Infect Dis; 2022 May; 103(1):115656. PubMed ID: 35231807
[TBL] [Abstract][Full Text] [Related]
29. Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19.
Dougan M; Nirula A; Azizad M; Mocherla B; Gottlieb RL; Chen P; Hebert C; Perry R; Boscia J; Heller B; Morris J; Crystal C; Igbinadolor A; Huhn G; Cardona J; Shawa I; Kumar P; Adams AC; Van Naarden J; Custer KL; Durante M; Oakley G; Schade AE; Holzer TR; Ebert PJ; Higgs RE; Kallewaard NL; Sabo J; Patel DR; Dabora MC; Klekotka P; Shen L; Skovronsky DM;
N Engl J Med; 2021 Oct; 385(15):1382-1392. PubMed ID: 34260849
[TBL] [Abstract][Full Text] [Related]
30. Emergence of the E484K mutation in SARS-COV-2-infected immunocompromised patients treated with bamlanivimab in Germany.
Jensen B; Luebke N; Feldt T; Keitel V; Brandenburger T; Kindgen-Milles D; Lutterbeck M; Freise NF; Schoeler D; Haas R; Dilthey A; Adams O; Walker A; Timm J; Luedde T
Lancet Reg Health Eur; 2021 Sep; 8():100164. PubMed ID: 34278371
[TBL] [Abstract][Full Text] [Related]
31. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
32. Evolution of spike mutations following antibody treatment in two immunocompromised patients with persistent COVID-19 infection.
Bronstein Y; Adler A; Katash H; Halutz O; Herishanu Y; Levytskyi K
J Med Virol; 2022 Mar; 94(3):1241-1245. PubMed ID: 34755363
[TBL] [Abstract][Full Text] [Related]
33. SARS-CoV-2 Spike Protein-Directed Monoclonal Antibodies May Ameliorate COVID-19 Complications in APECED Patients.
Ferré EMN; Schmitt MM; Ochoa S; Rosen LB; Shaw ER; Burbelo PD; Stoddard JL; Rampertaap S; DiMaggio T; Bergerson JRE; Rosenzweig SD; Notarangelo LD; Holland SM; Lionakis MS
Front Immunol; 2021; 12():720205. PubMed ID: 34504497
[TBL] [Abstract][Full Text] [Related]
34. A Randomized, Placebo-Controlled Clinical Trial of Bamlanivimab and Etesevimab Together in High-Risk Ambulatory Patients With COVID-19 and Validation of the Prognostic Value of Persistently High Viral Load.
Dougan M; Azizad M; Mocherla B; Gottlieb RL; Chen P; Hebert C; Perry R; Boscia J; Heller B; Morris J; Crystal C; Igbinadolor A; Huhn G; Cardona J; Shawa I; Kumar P; Blomkalns A; Adams AC; Van Naarden J; Custer KL; Knorr J; Oakley G; Schade AE; Holzer TR; Ebert PJ; Higgs RE; Sabo J; Patel DR; Dabora MC; Williams M; Klekotka P; Shen L; Skovronsky DM; Nirula A
Clin Infect Dis; 2022 Aug; 75(1):e440-e449. PubMed ID: 34718468
[TBL] [Abstract][Full Text] [Related]
35. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD
Elife; 2020 Oct; 9():. PubMed ID: 33112236
[TBL] [Abstract][Full Text] [Related]
36. Failure of bamlanivimab with selection of E484K mutation in an allogeneic stem cell transplant recipient with nosocomial SARS-CoV-2 infection.
Boussen I; Salmona M; Sicre De Fontbrune F; Xhaard A; De Castro N; Delaugerre C; Chaix ML; Molina JM
Antivir Ther; 2024 Feb; 29(1):13596535221097495. PubMed ID: 38353416
[TBL] [Abstract][Full Text] [Related]
37. Monoclonal antibodies targeting two immunodominant epitopes on the Spike protein neutralize emerging SARS-CoV-2 variants of concern.
Kovacech B; Fialova L; Filipcik P; Skrabana R; Zilkova M; Paulenka-Ivanovova N; Kovac A; Palova D; Rolkova GP; Tomkova K; Csokova NT; Markova K; Skrabanova M; Sinska K; Basheer N; Majerova P; Hanes J; Parrak V; Prcina M; Cehlar O; Cente M; Piestansky J; Fresser M; Novak M; Slavikova M; Borsova K; Cabanova V; Brejova B; Vinař T; Nosek J; Klempa B; Eyer L; Hönig V; Palus M; Ruzek D; Vyhlidalova T; Strakova P; Mrazkova B; Zudova D; Koubkova G; Novosadova V; Prochazka J; Sedlacek R; Zilka N; Kontsekova E
EBioMedicine; 2022 Feb; 76():103818. PubMed ID: 35078012
[TBL] [Abstract][Full Text] [Related]
38. Exploratory data on the clinical efficacy of monoclonal antibodies against SARS-CoV-2 Omicron variant of concern.
Mazzaferri F; Mirandola M; Savoldi A; De Nardo P; Morra M; Tebon M; Armellini M; De Luca G; Calandrino L; Sasset L; D'Elia D; Sozio E; Danese E; Gibellini D; Monne I; Scroccaro G; Magrini N; Cattelan A; Tascini C; ; Tacconelli E
Elife; 2022 Nov; 11():. PubMed ID: 36413383
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
